http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20372529

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Multicenter Study
endingPage 1347
issn 1573-0646
0167-6997
issueIdentifier 5
pageRange 1335-1347
publicationName Investigational New Drugs
startingPage 1335
bibliographicCitation Jeong H, Hong YS, Kim JE, Lim HS, Ahn JB, Shin SJ, Park YS, Kim ST, Han SW, Kim TY, Kim TW. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2021 Oct;39(5):1335–47. doi: 10.1007/s10637-021-01110-9. PMID: 33829355.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cec1d65817aa19fce8b3bb0cf4dfdeca
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8fee6c0d6a0f7a34eb6ee72e2e2bd93a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26af0b246894b6090763d84ea4d56385
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3f2cd76bcd147aa52c0447393dc8493
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_15c948ce5edb69324a83465c2231c60c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d03875c0dcaa3e535e36f022212a3b02
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8570dd1688ae5d99248396a5b415261
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_259f06f7fd99b9717a94a7d5b1d7c79d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f51ae020e052a33ffb4b247d981314f7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b265dd0bc195bcba3cf999ca90dd0d9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d78e52f535a2755f491a9ad8381a2c4
date 2021-04-07^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/33829355
https://doi.org/10.1007/s10637-021-01110-9
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372
https://portal.issn.org/resource/ISSN/1573-0646
https://portal.issn.org/resource/ISSN/0167-6997
language English
source https://scigraph.springernature.com/
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
discusses http://id.nlm.nih.gov/mesh/M0022497
http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0550185
http://id.nlm.nih.gov/mesh/M0147530
http://id.nlm.nih.gov/mesh/M0002366
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D015179Q000188
http://id.nlm.nih.gov/mesh/D000970Q000627
http://id.nlm.nih.gov/mesh/D014633Q000031
http://id.nlm.nih.gov/mesh/D001577Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D001577Q000008
http://id.nlm.nih.gov/mesh/D006207
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D000077982
http://id.nlm.nih.gov/mesh/D001577Q000009
http://id.nlm.nih.gov/mesh/D000077146Q000627
http://id.nlm.nih.gov/mesh/D000970Q000008
http://id.nlm.nih.gov/mesh/D000970Q000009
http://id.nlm.nih.gov/mesh/D014633Q000493
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D019540
http://id.nlm.nih.gov/mesh/D014633Q000627
http://id.nlm.nih.gov/mesh/D014633Q000009
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D014633Q000008
http://id.nlm.nih.gov/mesh/D000970Q000493
http://id.nlm.nih.gov/mesh/D053208
http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D001577Q000493
http://id.nlm.nih.gov/mesh/D015179Q000473
http://id.nlm.nih.gov/mesh/D020714
http://id.nlm.nih.gov/mesh/D008657
http://id.nlm.nih.gov/mesh/D004305
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D009362
http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8198
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f3de48576c4f3fd4a284d1f8519d0483
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46929961
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7920

Showing number of triples: 1 to 81 of 81.